Add to Favorites Newsroom RSS Share
fb-shareSbarro Health Research Organization (SHRO)
Philadelphia, PA USA

Our News on Newswise

Newswise: IMG_1376.JPG

Virtual Reality and Breast Cancer, First Italian-American Study Shows Promising Results

Virtual Reality during chemotherapy shown to improve breast cancer patients’ quality of life during the most stressful treatments, according to a recent study.
16-Jan-2020 3:05 PM EST Add to Favorites

Natural Extract to Counter Nephrotoxicity Induced by Mycotoxin OTA

Today a team of researchers from the Department of Veterinary Medicine and Animal Production of the Federico II University of Naples, in collaboration with the Sbarro Health Research Organization (SHRO), at Temple University in Philadelphia, and the...
7-Jan-2020 12:50 PM EST Add to Favorites

Turmeric and the Anti-Cancer Properties of Curcumin Discussed in Research Review

The review has collected studies concerning the anticancer potential of curcumin against the most widespread cancers and also describing the molecular mechanisms of action.
30-Dec-2019 4:35 PM EST Add to Favorites

Researchers Probe Emerging Mesothelioma Treatment Targeting PP2A and CDK

A collaborative study of researchers from Thomas Jefferson University, Sbarro Institute for Cancer Research and Molecular Medicine of Temple University, University of Siena, and from the Spanish Center for the Applied Medical Research (CIMA) of the...
24-Dec-2019 10:20 AM EST Add to Favorites

Land of Fires: Evaluation of heavy metal blood-levels in populations exposed to toxic waste in southern Italy

Toxic environmental agents, to which anyone is involuntarily exposed, represent non-negligible risk for human health and, therefore, environmental contamination has become a theme of primary importance worldwide.
5-Dec-2019 10:55 AM EST Add to Favorites

Gene Involved in Tumor Blood Vessel Formation and Metastasis Reveals New Regulatory Secrets


5-Dec-2019 9:00 AM EST Add to Favorites

Newswise: shroniaf.jpg

Medicine, Media & Patients: A New Professional Language

Panel to Convene at Annual Medical conference at NIAF
31-Oct-2019 8:55 AM EDT Add to Favorites

Newswise: giordanoawardcolombus.jpg

SHRO Founder Presented with Career Award and Appointed Chair of Italian Cancer Association FONICAP

Sbarro Health Research Organization founder and Director, Antonio Giordano, M.D., Ph.D., has been recognized with a career award "for the great contributions he has made and which he will continue to make to science, medicine and research.
21-Oct-2019 10:00 AM EDT Add to Favorites


see all news

Our Experts on Newswise

Cancer DNA Sequencing Has Potential, but Not a Magic Bullet, Says Expert

16-Jan-2018 11:05 AM EST

Newswise: Slide1.jpg

Thorough Genotyping and Repurposed Drugs Key to Treating Small-Cell Lung Cancer, says Cancer Expert

Cancer expert Antonio Giordano, MD, PhD, Director of the Sbarro Institute for Cancer Research and Molecular Medicine at Temple University, describes the recent progress and future possibilities of treating SCLC.
13-Apr-2017 7:05 AM EDT

Newswise: giordanoheadshot.png

Every Diagnosis of Cancer Should Come with One of These, Says Cancer Expert

“Every cancer diagnosis should come with a referral to genetic counseling,” says cancer expert Dr. Antonio Giordano, President of the Sbarro Health Research Organization at Temple University.
8-Feb-2017 10:30 AM EST

see all experts

Our YouTube Videos

Youtube feed not yet configured. Is this your Newswise member page? Contact member@newswise.com to configure this module.

About

Sbarro Health Research Organization conducts research in cancer, diabetes, and cardiovascular disease. Based in Philadelphia, Pennsylvania on the campus of Temple University, our programs train young scientists from around the globe.

Experts

  • Antonio Giordano

    President

    Keywords:
    Cancer, Diabetes, Heart Disease, Genetics, biomolecular chemistry, Oncology
     
     

Contacts

Barbara Colombo

barbaracolombo@ble-group.com

Antonio Giordano
President

president@shro.org

+1215-204-9520

Twitter twitter-icon

Chat now!
0.34746